09/03/2026
There’s a new name showing up in weight-loss research conversations: CagriSema. Here’s what the actual data shows.
It’s a combination of two medications working through different pathways — semaglutide (the GLP-1 you already know) and cagrilintide, which mimics amylin, a fullness hormone your pancreas releases after eating. The idea is that targeting two pathways instead of one could produce a stronger effect than either alone.
In the Phase 3 REDEFINE 1 trial, participants saw an average 20.4% weight reduction over 68 weeks, compared to 3.0% with placebo. Notable numbers — but context matters. When researchers compared it directly to tirzepatide in a 2026 trial, the results were closer than expected (23.0% vs. 25.5%), and CagriSema didn’t quite prove it performs at least as well.
What this really tells us: there’s probably not one “best” medication for everyone. The future of weight management is looking more personalized — different pathways, matched to different people.
CagriSema is still working its way through clinical trials, and we’ll be watching closely as more data comes in.